SPDR S&P Biotech ETF (XBI)
| Assets | $6.73B |
| NAV | $123.95 |
| Expense Ratio | 0.35% |
| PE Ratio | 14.55 |
| Shares Out | 54.28M |
| Dividend (ttm) | $0.22 |
| Dividend Yield | 0.17% |
| Ex-Dividend Date | Mar 22, 2021 |
| 1-Year Return | - |
| Volume | 6,441,612 |
| Open | 123.67 |
| Previous Close | 123.84 |
| Day's Range | 121.96 - 124.23 |
| 52-Week Low | 109.91 |
| 52-Week High | 174.74 |
| Beta | 1.22 |
| Holdings | 190 |
| Inception Date | Jan 31, 2006 |
About XBI
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (S&P TMI).
Top 10 Holdings
9.89% of assets| Name | Symbol | Weight |
|---|---|---|
| ChemoCentryx | CCXI | 1.75% |
| Acceleron Pharma | XLRN | 1.01% |
| Cytokinetics | CYTK | 0.94% |
| Ocugen | OCGN | 0.91% |
| Kodiak Sciences | KOD | 0.91% |
| Seagen | SGEN | 0.88% |
| Iovance Biotherapeutics | IOVA | 0.88% |
| Bluebird Bio | BLUE | 0.88% |
| ACADIA Pharmaceuticals | ACAD | 0.86% |
| Global Blood Therapeutics | GBT | 0.86% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 22, 2021 | $0.040 | Mar 25, 2021 |
| Dec 21, 2020 | $0.176 | Dec 24, 2020 |
| Sep 21, 2020 | $0.08897 | Sep 24, 2020 |
| Jun 22, 2020 | $0.01676 | Jun 25, 2020 |
| Dec 20, 2019 | $0.00086 | Dec 26, 2019 |
| Sep 20, 2019 | $0.00319 | Sep 25, 2019 |
News
Can Biotech ETFs Gain From Positive Booster Update?
In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.
Is the biotech sell-off a buying opportunity
Jared Holz, Oppenheimer, on whether the dip in biotech is an opportunity for investors. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen Finerman and Jeff Mills.
MPM's Bardon on biotech investing outlook, $850 million oncology fund
Dr. Christiana Bardon, co-managing partner of MPM's BioImpact Capital, joins CNBC's 'Squawk Box' to discuss the public and private biotech investing landscape.
Stocks to Correct 5-10% in 2021? Buy These ETFs
Some market watchers are raising concerns about overvaluation in the market. Investors can thus bet on these undervalued but top-ranked ETFs.
5 Top ETFs With Great Value & More Room for Growth
The S&P 500 has been in a great shape this year, calling for overvaluation concerns. Why not investing in ETFs that have underperformed the S&P 500, have a lower P/E and have a Buy rating.
Top ETF Stories of August
Taper talks, the Senate approval of the infrastructure bill, upbeat earnings, FDA Approval for Pfizer COVID-19 Vaccine and recovery of China ETFs were the key highlights of the broader global markets in...
COVID Biotech ETFs Rise At Fever Pace
ETFs that look at a subsector of biotech have significantly outperformed broader biotech funds this year.
Hopes of Moderna (MRNA) Vaccine Approval Boost Biotech
Biotech ETFs shot higher after the FDA formally approved Pfizer's vaccine. Trade the group's two largest funds with these tactical ideas.
Small-Cap Biotech Stocks Are Having a Rough Year, But That Could Change in a Heartbeat
While the world's leading biotech companies — churning out Covid-19 vaccines and treatments — have hit record share prices, their.
3 Stocks to Buy for the Second Half of 2021
Even at all time high indices there are stocks to buy. Today we find three swing trade opportunities while the bulls are in charge.
IBB Vs. XBI: Which Biotech ETF Has A Better Chart?
The SPDR S&P Biotech ETF (NYSE: XBI) is trading below an important resistance level, but the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) has broken out. Resistance is a large group of sellers who are...
3 Biotech ETFs That Could Double Your Money by 2025 With Zero Effort
In a sector where picking individual stocks is a high-risk, high-reward strategy, the diversification of exchange-traded funds can be highly appealing.
Biotech ETFs Surge on Biogen's Alzheimer Drug Approval
The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.
3 Top Stock Trades for the Week
These three ETFs were red-hot on Monday, making them obvious choices for this week's top stock trades. Here's how to play them with options.
